- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07521007
En fase 2b klinisk studie av YN001 hos voksne med koronar aterosklerose (PURIFY-TIMI 81)
En randomisert, multiklinisk, dobbeltblind, parallell, placebokontrollert fase 2b klinisk studie for å evaluere effekt og sikkerhet av YN001 hos voksne med koronar aterosklerose
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Jingmei Zhang, Master
- Telefonnummer: 0086 010 82599080
- E-post: zhangjingmei@innovmedicine.com
Studer Kontakt Backup
- Navn: Kaiqi Zong, Master
- Telefonnummer: 0086 010 82599080
- E-post: zongkaiqi@innovmedicine.com
Studiesteder
-
-
New South Wales
-
Penrith, New South Wales, Australia, 2750
- Rekruttering
- Cannopy Clinical Research
-
Ta kontakt med:
- Karen Kaluhin, MD
- Telefonnummer: 0061 0491 276 512
- E-post: kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane, Queensland, Australia, 4064
- Rekruttering
- Core Research Group Pty Ltd.
-
Ta kontakt med:
- David Colquhou, MD
- Telefonnummer: 614-1184-2788
- E-post: d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N., Victoria, Australia, 3025
- Rekruttering
- Canopy Clinical Research
-
Ta kontakt med:
- Oscar Walsh, MD
- Telefonnummer: 0061 03 9968 7601
- E-post: owalsh@canopycr.com.au
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Har ikke rekruttert ennå
- St. Boniface Hospital
-
Ta kontakt med:
- Shuangbo Liu
- Telefonnummer: 204-237-2793
- E-post: sliu@sbgh.mb.ca
-
-
Ontario
-
London, Ontario, Canada, N5A 5A5
- Har ikke rekruttert ennå
- London Health Sciences Centre
-
Ta kontakt med:
- Habib Khan
- Telefonnummer: 519-663-3197
- E-post: habib.khan@lhsc.on.ca
-
North York, Ontario, Canada, M6B 3H7
- Har ikke rekruttert ennå
- North York Diagnostic and Cardiac Centre
-
Ta kontakt med:
- Subodh Verma, MD
- Telefonnummer: 416-436-0244
- E-post: subodh.verma@unityhealth.to
-
Toronto, Ontario, Canada, M5B 1W8
- Har ikke rekruttert ennå
- St. Michael's Hospital
-
Ta kontakt med:
- John Graham
- Telefonnummer: 416-864-6060
- E-post: John.Graham@unityhealth.to
-
Vaughan, Ontario, Canada, L6A 4N9
- Har ikke rekruttert ennå
- Cardiac Clinic
-
Ta kontakt med:
- Navneet Singh
- Telefonnummer: 905-417-3001
- E-post: navneet.singh@thp.ca
-
-
Toronto
-
Toronto, Toronto, Canada, M5G 2N2
- Har ikke rekruttert ennå
- Toronto General Hospital - University Health Network
-
Ta kontakt med:
- Jacob Udell
- Telefonnummer: 416-340-4800
- E-post: jay.udell@utoronto.ca
-
-
-
-
Alabama
-
Huntsville, Alabama, Forente stater, 35801-4312
- Rekruttering
- Heart Center Research, LLC
-
Ta kontakt med:
- Walter Haught, MD
- Telefonnummer: 256-519-8472
- E-post: hhaught@theheartcenter.md
-
-
California
-
Covina, California, Forente stater, 91740
- Har ikke rekruttert ennå
- Thrive Clinical Research Group, LLC
-
Ta kontakt med:
- Sami Hayek
- Telefonnummer: 818-280-4220
- E-post: samihayek82@hotmail.com
-
Ta kontakt med:
- E-post: shayek@foothillcardiology.com
-
Lincoln, California, Forente stater, 95648
- Har ikke rekruttert ennå
- Clinical Trials Research
-
Ta kontakt med:
- Jeffrey Wayne, MD
- Telefonnummer: 916-434-8230
- E-post: jwaynemd@ctrsites.com
-
Los Alamitos, California, Forente stater, 90720
- Har ikke rekruttert ennå
- University of California Irvine Medical Center - Cardiovascular Center
-
Ta kontakt med:
- Arnold Seto
- Telefonnummer: 562-598-3200
- E-post: arnold.seto@va.gov
-
Stanford, California, Forente stater, 94305-2200
- Har ikke rekruttert ennå
- Stanford Health Care General Cardiology
-
Ta kontakt med:
- Fahim Abbasi, MD
- Telefonnummer: 650-723-6459
- E-post: fahim@stanford.edu
-
Torrance, California, Forente stater, 90502-2006
- Rekruttering
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Ta kontakt med:
- Matthew Budoff, MD
- Telefonnummer: 310-222-3641
- E-post: mbudoff@lundquist.org
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33434
- Har ikke rekruttert ennå
- Flourish Research - Boca Raton
-
Ta kontakt med:
- Richard Goldman
- Telefonnummer: 561-756-8206
- E-post: rgoldman@flourishresearch.com
-
Hialeah, Florida, Forente stater, 33016-1895
- Rekruttering
- New Generation of Medical Research, LLC.
-
Ta kontakt med:
- Karelia Ruiz
- Telefonnummer: 305-828-9100
- E-post: kareliar@ngmresearch.com
-
St. Petersburg, Florida, Forente stater, 33709
- Rekruttering
- HCA Florida Heart Institute
-
Ta kontakt med:
- Robert Sanchez, MD
- Telefonnummer: 727-490-2100
- E-post: robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30303-3049
- Har ikke rekruttert ennå
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
Ta kontakt med:
- Modele Ogunniyi
- Telefonnummer: 404-616-4440
- E-post: modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian, Idaho, Forente stater, 83642
- Har ikke rekruttert ennå
- St. Luke's Clinic - Idaho Cardiology Associates
-
Ta kontakt med:
- Brian Nolan
- Telefonnummer: 208-322-1680
- E-post: bnolan@slhs.org
-
-
Illinois
-
Springfield, Illinois, Forente stater, 62781
- Har ikke rekruttert ennå
- Southern Illinois University School of Medicine
-
Ta kontakt med:
- Abdul Hafiz, MD
- Telefonnummer: 217-545-8000
- E-post: ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66211-1215
- Rekruttering
- Midwest Heart & Vascular Specialists, LLC
-
Ta kontakt med:
- Stephen Bloom, MD
- Telefonnummer: 913-253-3000
- E-post: sbloom@kc.rr.com
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110-1032
- Rekruttering
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
Ta kontakt med:
- Farhan Katchi, MD
- Telefonnummer: 314-362-1291
- E-post: katchif@wustl.edu
-
-
North Carolina
-
Raleigh, North Carolina, Forente stater, 27607
- Har ikke rekruttert ennå
- NC Heart and Vascular Research, LLC
-
Ta kontakt med:
- Mohit Pasi
- Telefonnummer: 919-784-2300
- E-post: mohit.pasi2@unchealth.unc.edu
-
Winston-Salem, North Carolina, Forente stater, 27104-3520
- Har ikke rekruttert ennå
- Javara Inc. - Wake Forest University Health Sciences
-
Ta kontakt med:
- Michael Shapiro, MD
- Telefonnummer: 336-713-7251
- E-post: owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45219
- Har ikke rekruttert ennå
- The Christ Hospital
-
Ta kontakt med:
- Mark Berlacher, MD
- Telefonnummer: 513-585-1777
- E-post: Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73135
- Har ikke rekruttert ennå
- South Oklahoma Heart Research, LLC
-
Ta kontakt med:
- Naeem Tahirkheli
- Telefonnummer: 405-628-6865
- E-post: ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Forente stater, 17011
- Rekruttering
- Capital Area Research, LLC - Camp Hill
-
Ta kontakt med:
- Venkatesh Nadar, MD
- Telefonnummer: 717-695-8722
- E-post: VNadar@care-research.com
-
-
Texas
-
Amarillo, Texas, Forente stater, 79106
- Rekruttering
- PharmaTex Research, LLC
-
Ta kontakt med:
- David Brabham
- Telefonnummer: 806-355-2581
- E-post: dgbrabham@hotmail.com
-
Carrollton, Texas, Forente stater, 75010
- Har ikke rekruttert ennå
- Pulse Care Heart and Vascular
-
Ta kontakt med:
- Kiran Kumar Mangalpally
- Telefonnummer: 214-407-8640
- E-post: trials@stryderesearch.com
-
Tomball, Texas, Forente stater, 77375
- Har ikke rekruttert ennå
- DM Clinical Research - Dallas
-
Ta kontakt med:
- Mustafa Mandviwala
- Telefonnummer: 346-550-9559
- E-post: drmandviwala.ns@dmclinical.com
-
-
-
-
An
-
Hefei, An, Kina, 230022
- Rekruttering
- The First Affiliated Hospital of Anhui Medical Unversity
-
Ta kontakt med:
- Jianlong Wang, MD
- Telefonnummer: 0086-13681292304
- E-post: Wjlmll@sina.com
-
-
Anhui
-
Hefei, Anhui, Kina, 230001
- Rekruttering
- Anhui Provincial Hospital
-
Ta kontakt med:
- Kangyu Chen, MD
- Telefonnummer: 0086 18056005099
- E-post: ustccky@126.com
-
Hovedetterforsker:
- Kangyu Chen, MD
-
Underetterforsker:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100035
- Rekruttering
- Beijing Jishuitan Hospital
-
Hovedetterforsker:
- Wei Liu, MD
-
Ta kontakt med:
- Qingwei Ji, MD
- Telefonnummer: 0086 18376642655
- E-post: jqwl24@163.cou
-
Hovedetterforsker:
- Qingwei Ji, MD
-
Beijing, Beijing Municipality, Kina, 100029
- Rekruttering
- Anzhen Hospital
-
Ta kontakt med:
- Yuyang Liu, MD
- Telefonnummer: 0086 010-64456488
- E-post: liuyy803803@163.com
-
Hovedetterforsker:
- Yuyang Liu, MD
-
Beijing, Beijing Municipality, Kina, 101100
- Har ikke rekruttert ennå
- Beijing Luhe Hospital
-
Ta kontakt med:
- Guangyao Zhai, MD
- Telefonnummer: +86 1069543901
- E-post: drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350001
- Rekruttering
- Fujian Medical University Union Hospital
-
Ta kontakt med:
- Mingfang Ye, MD
- Telefonnummer: 0086 13960818759
- E-post: xieheyemingfang@163.com
-
Hovedetterforsker:
- Mingfang Ye, MD
-
Underetterforsker:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou, Gansu, Kina, 730030
- Rekruttering
- The Second Hospital & Clinical Medical School Lanzhou University
-
Ta kontakt med:
- Feng Bai, MD
- Telefonnummer: 0086-13609363049
- E-post: baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Rekruttering
- Guangdong Provincial People's Hospital
-
Ta kontakt med:
- Ning Tan, MD
- E-post: tanning100@126.com
-
Ta kontakt med:
- Telefonnummer: 0086-13903073651
- E-post: tangning100@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, Kina, 163316
- Rekruttering
- Daqing People's Hospital
-
Ta kontakt med:
- Shu Zhang
- Telefonnummer: +86-459-6612898
- E-post: dqsrmyygcp@163.com
-
Harbin, Heilongjiang, Kina, 150001
- Rekruttering
- The First Affiliated Hospital of Harbin Medical University
-
Ta kontakt med:
- Lu Fu, MD
- Telefonnummer: 0086 137 9668 4968
- E-post: fuluyidayi@163.com
-
Hovedetterforsker:
- Lu Fu, MD
-
Hovedetterforsker:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan, Hubei, Kina, 430071
- Rekruttering
- Zhongnan Hospital of Wuhan University
-
Ta kontakt med:
- Xiaorong Hu, MD
- Telefonnummer: 0086 15927681634
- E-post: huzrzn@whu.edu.cn
-
Hovedetterforsker:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Rekruttering
- The Second Xiangya Hospital fo Central South University
-
Ta kontakt med:
- Xinqun Hu, MD
- Telefonnummer: 0086-13307313627
- E-post: huxinqungs@163.com
-
-
Jilin
-
Changchun, Jilin, Kina, 130033
- Rekruttering
- The First Hospital of Jilin University
-
Hovedetterforsker:
- Qian Tong, MD
-
Ta kontakt med:
- Qian Tong, MD
- Telefonnummer: 0086 13074337289
- E-post: tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110015
- Rekruttering
- The People's Hospital of Liaoning Province
-
Hovedetterforsker:
- Ying Liu, MD
-
Ta kontakt med:
- Ying Liu, MD
- Telefonnummer: 0086 13840065379
- E-post: liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710068
- Rekruttering
- Shaanxi Provincial People's Hospital
-
Ta kontakt med:
- Xiling Shou, MD
- Telefonnummer: 0086 18966700335
- E-post: shouxiling@163.com
-
-
Shandong
-
Jinan, Shandong, Kina
- Rekruttering
- Central Hospital Affiliated to Shandong First Medicial University
-
Ta kontakt med:
- Guohai Su, MD
- Telefonnummer: 0086 19953193319
- E-post: gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Rekruttering
- Fudan University-Zhongshan Hospital
-
Hovedetterforsker:
- Junbo Ge, MD
-
Ta kontakt med:
- Junbo Ge, MD
- Telefonnummer: 021-64041990
- E-post: ge.junbo@zs-hospital.sh.cn
-
Underetterforsker:
- Yuxiang Dai, MD
-
Shanghai, Shanghai Municipality, Kina, 200001
- Rekruttering
- Renji Hospital Shanghai Jiaotong University school of medicine
-
Ta kontakt med:
- Jun Bu, MD
- Telefonnummer: 0086 13601958108
- E-post: pujun310@hotmail.com
-
Hovedetterforsker:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- West China Hospital of Sichuan University
-
Ta kontakt med:
- Yong He, MD
- Telefonnummer: 0086 18980602038
- E-post: zznnyeah@163.com
-
Hovedetterforsker:
- Yong He, MD
-
Chengdu, Sichuan, Kina, 610072
- Rekruttering
- Sichuan Provincial People's Hospital
-
Ta kontakt med:
- Jianhong Tao, DM
- Telefonnummer: 86-189 8183 8875
- E-post: Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300211
- Rekruttering
- The Second Hospital of Tianjin Medical University
-
Ta kontakt med:
- Tong Liu, MD
- Telefonnummer: 0086 13902183163
- E-post: liutongdoc@126.com
-
Hovedetterforsker:
- Tong Liu, MD
-
Tianjin, Tianjin Municipality, Kina, 300121
- Rekruttering
- Tianjin People's Hospital
-
Hovedetterforsker:
- Zhuhua Yao, MD
-
Ta kontakt med:
- Zhuhua Yao, MD
- Telefonnummer: 0086 13902199877
- E-post: tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310006
- Rekruttering
- Zhejiang Provincial People's Hospital
-
Ta kontakt med:
- Lihong Wang, MD
- Telefonnummer: 0086-13666690598
- E-post: wlhhz@hotmail.com
-
Suzhou, Zhejiang, Kina, 215006
- Rekruttering
- The First Affiliated Hospital of Soochow University
-
Ta kontakt med:
- Tingbo Jiang, MD
- Telefonnummer: 0086-18906201122
- E-post: jiangtingbo6797@163.com
-
Wenzhou, Zhejiang, Kina, 325000
- Rekruttering
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
Ta kontakt med:
- lianpin Wu, MD
- E-post: 198019@wzhealth.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Eksperimentell: Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Placebo komparator: Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
Tidsramme: Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsramme: From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Tidsramme: From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Tidsramme: From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Tidsramme: From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Tidsramme: From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Tidsramme: From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Tidsramme: From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
Tidsramme: From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Tidsramme: From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
Tidsramme: From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
Tidsramme: From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
Tidsramme: From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
Tidsramme: From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- YN001-203
- IND 157167 (Registeridentifikator: Beijing Inno Medicine Co., Ltd.)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .